Teva- Pharmaceutical Industries Ltd. TEVA

NYS: TEVA | ISIN: US8816242098   22:00
17,25 USD (-0,92%)
(-0,92%)   22:00
Grafiek Teva- Pharmaceutical Industries Ltd. Grafiek Teva- Pharmaceutical Industries Ltd.
woensdag 6 november 2024, 13:00
Kwartaalcijfers (3de kwartaal)

Teva- Pharmaceutical Industries Ltd. in het nieuws

8 oktober 2024 · Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA · Persbericht

3 oktober 2024 · Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate · Persbericht

1 oktober 2024 · Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. · Persbericht

30 september 2024 · Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024 · Persbericht

23 september 2024 · Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia · Persbericht

21 september 2024 · Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia · Persbericht

21 september 2024 · New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) · Persbericht

11 september 2024 · Teva to Present at the Bank of America 2024 Global Healthcare Conference · Persbericht

26 augustus 2024 · Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference · Persbericht

31 juli 2024 · Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance · Persbericht

Profiel Teva- Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd. is een Israëlische multinationale farmaceutische onderneming met hoofdkantoor in Tel Aviv, Israël. Het bedrijf is voornamelijk gespecialiseerd in generieke geneesmiddelen, maar heeft ook belangen in actieve farmaceutische ingrediënten en, in mindere mate, in farmaceutische specialiteiten.

Fabricage van farmaceutische preparaten
Farmaceutische Producten: Generisch
Gezondheidstechnologie
Productie

CEO: Kaare Schultz

Werknemers: 37.736

Aandelen Teva- Pharmaceutical Industries Ltd.

Beurswaarde: 21,03 miljard USD

Effecten: 1,13 miljard

Winst per aandeel (12 maand):  PLUS

Beta: 0,83

Mijn selecties